Gubra AS (STU:PI3) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PI3 Gubra AS STU:PI3
61 GF Score
Price €44.78
GF Value €385.02
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Gubra AS Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:PI3
61GF Score
Gubra AS STU:PI3
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gubra AS (STU:PI3) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of €44.78 is trading 88.4% below its estimated GF Value™ of €385.02. GuruFocus considers Gubra AS to be Possible Value Trap.

Key valuation signals for STU:PI3:

  • Interest Received:
  • GF Value™: €385.02 vs. price of €44.78 (88.4% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the STU:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gubra AS Business Description

Other Exchanges GUBRA:Denmark
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
61GF Score

Get the complete analysis for STU:PI3

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€44.78
Price
€385.02
GF Value